Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 4.9% Following Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price traded down 4.9% during mid-day trading on Friday following insider selling activity. The stock traded as low as $6.52 and last traded at $6.57. 1,149,152 shares changed hands during trading, a decline of 80% from the average session volume of 5,710,360 shares. The stock had previously closed at $6.91.

Specifically, CFO Michael Secora sold 15,000 shares of the business's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the sale, the chief financial officer now owns 1,499,631 shares of the company's stock, valued at $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Blake Borgeson sold 11,447 shares of the business's stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $7.64, for a total value of $87,455.08. Following the completion of the sale, the director now owns 7,066,113 shares in the company, valued at $53,985,103.32. This represents a 0.16 % decrease in their position. The disclosure for this sale can be found here.

Wall Street Analyst Weigh In

A number of research firms have issued reports on RXRX. Jefferies Financial Group reduced their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a report on Tuesday, September 3rd. Needham & Company LLC reissued a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, November 7th. Finally, Leerink Partners reduced their target price on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a report on Tuesday, September 3rd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $9.25.

Recursion Pharmaceuticals Stock Performance

The company has a market cap of $1.74 billion, a PE ratio of -4.08 and a beta of 0.81. The stock's 50-day simple moving average is $6.65 and its 200 day simple moving average is $7.61. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). The business had revenue of $26.08 million during the quarter, compared to analyst estimates of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue was up 147.6% compared to the same quarter last year. During the same period last year, the business posted ($0.43) EPS. As a group, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC acquired a new position in Recursion Pharmaceuticals during the 3rd quarter worth approximately $25,000. Farther Finance Advisors LLC lifted its position in Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after purchasing an additional 4,091 shares during the last quarter. GAMMA Investing LLC increased its stake in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company's stock valued at $48,000 after buying an additional 6,036 shares during the period. KBC Group NV raised its holdings in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Finally, Amalgamated Bank lifted its holdings in shares of Recursion Pharmaceuticals by 52.4% during the second quarter. Amalgamated Bank now owns 7,152 shares of the company's stock valued at $54,000 after purchasing an additional 2,459 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.